Sun Pharmaceutical Industries announced that it has settled a litigation with The Medicines Company, USA for a generic version of Angiomax, Bivalirudin injection.
Under the terms of the settlement agreement, the Company's subsidiary is entitled to launch its version of generic Angiomax in the United States on 30 June 2019 or earlier under certain limited circumstances.
Powered by Capital Market - Live News
